Staphylococcus aureus (MRSA) strains from patients and hospital environments has becoming higher and higher in recent years1'2*. MRSA is now one of the most important pathogens of the nosocomial infections in Japan3A). No doubt, this is ascribed to the very low susceptibility of MRSAstrains to various chemotherapeutic agents3~6). Arbekacin (ABK) [l-iV-(S)-4 amino-2-hydroxybutyryl-3',4'-dideoxykanamycin B] , a semisynthetic aminoglycosidic antibiotic has recently become into clinical use, and its efficacy has been reported7~9).
This led us to re-evaluate the in vitro activity of the ABK against MRSA isolates together with other chemotherapeutic agents in current use for comparison, as the ABKis now considered to be one of the few drugs effective for the treatment of patients with MRSA infection.
MRSAStrains Examined
A total of 496 MRSAstrains, isolated during the years 1989 to 1992 from clinical specimens submitted to our laboratory, was used in this study.
They were comprised of 82 strains from pharyngeal swab, 84 from urine, 185 from pus, 90 from nose, 25 from sputum,and 30 from miscellaneous materials which included the 16 from blood specimens. Only one strain from each patient was served for the examination. These strains were identified as S. A loopful of the suspension (15jA) was streaked on the agar plates. The results were read after incubation at 35°C for 48 hours.
Resistance of the MRSAStrains
Results of the tests are summarized in Table 1 . Presented in the Table were the MICs that inhibited the growth of the 50% (MIC50) and 90% (MIC90) strains from each of the sources. No MRSAstrain was inhibited its growth by DMPPCat the concentration of lower than 12.5 /zg/ml and MIC90of this drug against the strains tested were higher than 800//g/ml. Both ABKand VCMwere more active than any other drugs examined. Twostrains were demonstrated to be resistant to ABK.The MICs of the resistant strains were 12.5^g/ml and 25 jWg/ml, respectively. The former was isolated from pus of otitis media and the latter came from urine of a patient with urinary tract infection. The two strains were also resistant to KM, DKB, AMK, TOB, GM, SISO, NTL, MCR, ISP, NM, RSM, LVM, BUTY, ASTM but sensitive to streptomycin. This result The concentrations of the drugs required to inhibit the growth of 50% (MIC50) and 90%(MIC90) of the total number of MRSAstrains tested. A criticism to our results would be that, as the strains examined had been isolated from a limited environment, that is, only in our hospital, hence the results may not represent the susceptibility of MRSAstrains now widely distributed in Japan.
However, the number of resistant pattern of our strains for the ten agents tested counted twelve, but none of them was predominant (data not shown). Wehave also classified approximately one hundred isolates amongthe strains tested into the eleven types by Pulsed Field Gel Electrophoresis for the genomic DNAsdigested with Smal and in this case, noneof the type was significantly prevalent nor associated with a particular drug resistant pattern (data not shown). Wesince did not consider that the strains used represented only a few numberof clones of the MRSAstrains that were distributed in our hospital during the period we isolated them. 
